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1. Introduction
  The influenza severity ranges from asymptomatic infection 
to serious illness with systemic features especially in 
patients with pre-existing respiratory or cardiovascular 
disease and in frail elderly. Influenza viruses have a 
segmented genome of negative sense RNA encapsidated by 
a virally specified nucleoprotein. There are three types of 
influenza viruses A, B and C that cause illness in human 
population. Influenza B and C viruses are essentially 
restricted to humans whereas influenza A viruses infect a 
wide variety of avian and mammalian species[1,2]. Influenza 
A viruses can be divided into 16 subtypes of hemagglutinin 
(HA) and 9 different subtypes of neuraminidase (NA) based 
on both antigenic and genetic differences[3-5]. Human 
influenza is a zoonotic disease, and aquatic birds form the 
major natural reservoir of influenza A viruses of all HA and 
NA subtypes[6]. Despite that, pigs play an important role in 
the ecology of human influenza. One of the most important 
biological properties of influenza A viruses is their antigenic 
variability which occurs in two forms: antigenic drift and antigenic 
shift. Pigs, considered as an intermediate host, possess both 
receptors NeuAc毩2,6Gal linkages and NeuAc毩2,3Gal linkages 
for human  and avian influenza viruses respectively on 
their respiratory epithelial cells, and this explains the 
susceptibility of pigs to both avian and human influenza 
viruses[7]. For this, pigs have been postulated to be as a 
mixing vessel for the emergence of new isolates with human 
pandemic potential[8]. Influenza virus caused seasonal 
epidemics and occasional pandemics in humans. Three 
major global pandemics caused by novel antigen variants 
of influenza viruses have affected the human population, 
the “Spanish flu” in 1918 (H1N1 subtype), the “Asian flu” 
in 1957 (H2N2 subtype), and the “Hong Kong flu” in 1968 
(H3N2 subtype) resulting in significant mortality during the 
20th century[9,10]. All these pandemics originated in whole 
or in part from nonhuman reservoirs, and the HA genes of 
all of the pandemic viruses ultimately originated from avian 
influenza viruses[11].
  In Spring 2009, a novel reassortant strain of H1N1 
influenza A emerged as a lineage distinct from seasonal 
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H1N1. This new H1N1 virus has now migrated to most parts 
of the Americas, Europe, Australia, Asia and Africa. Its 
hemagglutinin (HA), nucleoprotein (NP), and nonstructural 
(NS) protein genes belong to the classical swine lineage, 
while its neuraminidase (NA) and matrix (M) protein 
genes derive from a Eurasian swine influenza lineage 
which entered pigs from avian hosts around 1979, and its 
polymerase gene segments, PA, PB1 and PB2, descended from 
the North American triple reassortant swine lineage[11-13]. 
This genetic combination may contribute to the improved 
fitness of the H1N1 pdm in humans and its human-to-
human transmissibility. There is a serious concern that the 
virus may further mutate into a more dangerous form, so it is 
very important to monitor the evolutionary trends of the 2009 
H1N1 pdm virus.
  On April 17, 2009, CDC determined that two cases of febrile 
respiratory illness occurring in children who resided in 
adjacent counties in southern California were caused by 
infection with a swine influenza A (H1N1) virus[14]. On 
June 11, 2009, the World Health Organization declared the 
outbreak of novel H1N1 virus had become the first global 
pandemic of the 21st century[15]. The virus was found to be an 
H1N1 virus that was antigenically and genetically unrelated 
to human seasonal influenza viruses and genetically related 
to viruses known to circulate in swine. The name of this 
pandemic virus is influenza A/H1N1 pdm [16].
  Each year, WHO publishes recommendations on the 
composition of influenza vaccine for the Northern and 
Southern Hemispheres. There are currently two main 
branches of H1N1 circulating world-wide including the 
Middle East (ME) region, a seasonal branch and a pandemic 
branch. In this paper, we focused on hemagglutinin genetic 
evolution of some ME 2009 H1N1 pdm isolates and compared 
them with prototype vaccine strain [A/California/07/2009 
(H1N1)], which is used as vaccine strain in the Northern 
Hemisphere 2010-2011[17].
2. Materials and methods
  Nucleotide and/or amino acid sequences of HA gene of 
ME 2009 H1N1 pdm isolates were retrieved from GenBank 
Database by using Basic BLAST engine (www.ch.embnet.
org/software/bBLAST.html). These isolates were recovered 
from different ME countries: Israel (n=4), Turkey (n=20), 
Iraq (n=1), Kuwait (n=13), Iran (n=3), Bahrain (n=4), Egypt 
(n=5), and Afghanistan (n=4). Other references strains were 
included in this study such as A/California/07/2009 (H1N1), 
A/South Carolina/1/18 (H1N1), A/Solomon Island/320/2006 
(H1N1), A/Brisban/59/2007 (H1N1), A/Korea/01/2009 (H1N1), 
A/Tokushima/1/2009 (H1N1), A/Beijing/3/2009 (H1N1) and 
A/Turkey/1558/2007 (H1N1). Phylogenetic trees were 
constructed based on the continuous nucleotide sequences 
and deduced amino acid sequences of the HA gene region 
including nucleotides 51-1184 (1133 nucleotides) and 
amino acids 17-394 (377 amino acids). Numbering of 
nucleotides and amino acids corresponding to positions 
of A/California/07/2009 (H1N1) strain sequence. The 
phylogenetic analysis was established by comparison with 
the representative seasonal strain from the ME region, 
prototype vaccine strain [A/California/07/2009 (H1N1)], H1N1 
influenza A seasonal vaccines, and other 2009 H1N1 pdm 
isolates. Multiple alignments were done using the muscle 
algorithm of the computer program CLC free workbench 5.6.1 
JRE software (developed by CLC bio A/S, www.clcbio.com). 
Phylogenetic trees were constructed using the program 
Neighbor Joining in the same software. The robustness of 
the groupings in the Neighbor Joining analysis was assessed 
with 1 000 bootstrap resamplings. Amino acids alignment 
was done to compare sequences HA1 domains of HA genes 
of ME 2009 H1N1 pdm isolates (n=39) with amino acid 
sequence of prototype vaccine strain A/California/07/2009 
(H1N1). ME 2009 H1N1 pdm isolates included in amino acid 
alignment are A/Israel/644/2009 (H1N1), A/Israel/276/2009 
(H1N1), A/Israel/277/2009 (H1N1), A/Israel/70/2009(H1N1), 
A/Sulaimani/05/2009 (H1N1), A/Ghom/1550/2009 (H1N1), A/
Khorasan/1583/2009 (H1N1), A/Lorestan/1599/2009 (H1N1), 
A/Ankara/29/2009 (H1N1), A/Ankara/28/2009 (H1N1), A/
Ankara/27/2009 (H1N1),  A/Ankara/22/2009 (H1N1),  A/
Ankara/21/2009 (H1N1),  A/Ankara/20/2009 (H1N1),  A/
Ankara /19/2009(H1N1) ,  A/Ankara /18/2009(H1N1) ,  A/
Ankara/17/2009 (H1N1),  A/Ankara/16/2009 (H1N1),  A/
Anka ra /15 /2009  (H1N1 ) ,  A /Anka ra /13 /2009  (H1N1 ) , 
Ankara/12/2009 (H1N1),  A/Ankara/11/2009 (H1N1),  A/
Ankara/10/2009 (H1N1),  A/Ankara/08/2009(H1N1),  A/
Ankara /06/2009(H1N1) ,  A/Ankara /05/2009(H1N1) ,  A/
Ankara/04/2009 (H1N1),  A/Ankara/03/2009 (H1N1),  A/
Kuwait/6379/2009 (H1N1), A/Kuwait/N13111/2009 (H1N1), A/
Kuwait/N13039/2009 (H1N1), A/Kuwait/N13055/2009 (H1N1), A/
Egypt/N11640/2009 (H1N1), A/Egypt/N11640/2009 (H1N1), A/
Egypt/N14644/2009 (H1N1), A/Bahrain/N11892/2009 (H1N1), 
A/Bahrain/N11660/2009 (H1N1), A/Afghanistan/N11216/2009 
(H1N1), A/Afghanistan/N10725/2009 (H1N1). Seasonal A/
Turkey/1558/2007(H1N1) isolate was included as a 
representative strain. 
3. Results
  1 133 nucleotides of HA nucleotide sequence and 377 
deduced amino acids of HA region sequences of ME 2009 
H1N1 pdm isolates were compared with prototype vaccine 
strain [A/California/07/2009 (H1N1)], seasonal influenza A 
H1N1strains and 2009 H1N1 pdm isolates. Influenza A virus 
strain A/California/07/2009 (H1N1) is used as a vaccine 
strain in the Northern Hemisphere 2010-2011. Phylogenetic 
analysis showed that the sequences of deduced amino acids 
and DNA nucleotide sequences of HA genes of ME 2009 H1N1 
pdm isolates were closely related to the recent prototype 
vaccine strain A/California/07/2009 (H1N1)-like strain (Figure 
1 and 2). 
  The putative antigenic sites, receptor-binding sites and 
potential N-linked glycosylation sites were analyzed (Data 
not shown). Four out five conserved amino acid residues in 
H1 influenza A virus have Tyr(Y)-94, Trp(W)-153, His(H)-
183 and Tyr(Y)-195 at the HA receptor-binding site. While 
the conserved amino acid number 5, which is amino acid 
Ser(S)-136 in ME 2009 H1N1 pdm isolates, mutated to amino 
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acid Thr(T). In addition to that, HA of the ME 2009 H1N1 
pdm isolates possessed Asp(D)-190 and Asp(D)-225 in 
the receptor binding site except in two isolates, A/Egypt/
N14645/2009 (H1N1) and A/Egypt/N11651/2009 (H1N1) which 
had Gly(G)-225 and Glu(E)-225, respectively. Other critical 
residues known to confer human specificity in H5 viruses, 
including E227, P221 and E216 were also noted in H1N1 pdm 
viruses as well as in the ME 2009 H1N1 pdm isolates.  It was 
also found that 32/39 of the ME 2009 H1N1 pdm isolates have 
a unique mutation in HA S206T.
  The patterns of the antigenic site in the HA gene can be 
observed by amino acid alignment (Data not shown). As for 
H1N1, four antigenic sites have already been defined, two 
strain-specific (Sa and Sb) and common antigenic sites (Ca 
and Cb) of the virus hemagglutinin. It was found that only 3 
strains had amino acid substitutions in antigenic site Ca at 
HA1 domain. These isolates are A/Egypt/N14645/2009 (H1N1), 
A/Egypt/N11651/2009 (H1N1) and A/Bahrain/N11892/2009 (H1N1) 
which had D225G , D225E and R209K, respectively. As 
expected, the ME 2009 H1N1 pdm isolates contain amino acid 
substitutions at putative antigenic sites when compared with 
seasonal H1 HA1 region. These isolates had five potential 
glycosylation sites (Asn-X-Ser/Thr conserved at positions 
Asn(N)-14, Asn(N)-26, Asn(N)-90, Asn(N)-279 and Asn(N)-290 in 
HA1 domain. 
4. Discussion
  Influenza virus genomes are well known to undergo 
antigenic drift or antigenic shift that enable escape from 
preexisting immunity and cause new outbreaks of influenza 
in animals and even humans[18,19], so influenza A viruses 
have ability to exhibit the greatest genetic diversity and 
change every year. Each year  WHO recommends the most 
suitable composition of influenza vaccine strains for the 
Northern and Southern Hemispheres. Phylogenetic analysis 
of amino acids and nucleotides of the HA gene of the ME 
2009 H1N1 pdm isolates confirmed their evolutionary 
position in cluster with prototype vaccine strain [(A/
California/07/2009 (H1N1)] which is used as a vaccine strain 
in the Northern Hemisphere 2010-2011. Comparison of 
the nucleotide and amino acid sequences of the HA region 
between ME 2009 H1N1 pdm isolates and prototype vaccine 
strain [A/California/07/2009 (H1N1)] showed they are closely 
related to the vaccine strain recommended for the Northern 
Figure 2. Phylogenetic tree based on the amino acid sequence of HA 
genes of selected 54 ME 2009 H1N1 pdm isolates. 
Prototype vaccine strain [A/California/07/2009 (H1N1)] and other 
H1N1 influenza viruses were included. The tree was bootstrapped with 
1  000 replicates, and the genetic distance corresponding is shown by 
the bar. Sequences in this study were obtained from GenBank.
Figure 1. Neighbour-joining phylogenetic tree based on the partial 
nucleotide sequence of HA genes of selected 54 ME 2009 H1N1 pdm 
isolates. 
Prototype vaccine strain (A/California/07/2009 (H1N1)) and other 
H1N1 influenza viruses were included. The tree was bootstrapped 
with 1 000 replicates, and the genetic distance corresponding is shown 
by the bar. Sequences in this study were obtained from GenBank.
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Hemisphere 2010-2011. In general, ME 2009 H1N1 pdm 
isolates have the same amino acids in antigenic site and 
are closely related to the prototype vaccine strain, which 
indicates that these viruses may have the same antigenicity 
of prototype vaccine strain 2010/2011. Vaccines containing 
A/California/7/2009 antigens stimulated anti-HA antibodies 
of similar titers against the vaccine virus and recent 
pandemic A (H1N1) viruses[17]. Variations in H1N1 isolates 
were predominantly located at the antigenic site, which is of 
interest for developing suitable vaccine strains[20]. This may 
suggest that using  A/California/07/2009 (H1N1) as a vaccine 
will be effective against ME 2009 H1N1 pdm isolates[17]. 
  HA of the ME 2009 H1N1 pdm isolates, as in other H1N1pdm 
viruses, possessed Asp(D)-190 and Asp(D)-225 in the 
receptor binding sites, as the terminal sialic acid binding 
specifically to the NeuAc毩2,6Gal amino acid linkage[20-23]. 
A correlation between the amino acid in position 225 of HA 
and virus receptor specificity has been described by many 
investigators[24-27]. Probably, viruses with Asp(D)-190 and/
or Asp(D)-225 may support the efficient transmissibility 
of these viruses in the human respiratory tract[21,28]. The 
D-225G and D-225E mutations were observed in two ME 
2009 H1N1 pdm isolates. Changes occurred at a site HA 
225 involved both antigen and receptor binding. In this 
paper we reported three variants D, G and E at this position. 
Two variants D and G were reported and also observed 
during the 1 918 pandemic[22,29]. Glycan microarray studies 
have shown that HA possessing D190 along with G225 had 
specificity for both 毩-2,3 linked glycan and 毩-2,6 linked 
glycan[22]. The significance of these mutations in terms of 
pathogenicity needs to be verified[21]. There are five key 
conserved amino acid residues within the receptor-binding 
site in HA1 domain H1 influenza A virus, Tyr(Y)-94, Ser(S)-
136, Trp(W)-153, His(H)-183 and Tyr(Y)-195[20,22,30,31]. These 
residues are relatively conserved and predicted to have a 
role in binding to human receptors. Since both Thr and Ser 
are polar hydrorhilic amino acids, substitution between them 
most likely maintains interactions and proper conformation 
of the binding pocket. Other amino acids in ME 2009 H1N1 
pdm isolates possessed at positions (G)-134, (V)-135, (A)-
137,138-(A), 155-(V), (L)-194, (R)-224, (Q)-226, 227-(Q), (G)-
228 and  (R)-229, are components of receptor-binding sites 
of the HA of H1N1 influenza viruses[32]. Among other critical 
residues known to confer human specificity in H5 viruses[22], 
E227, P221 and E216 were also noted in other 2009 H1N1pdm 
viruses including the ME 2009 H1N1 pdm isolates[21].
  Antigenically, the ME 2009 H1N1 pdm isolates are 
homogeneous. There have been only a few amino acid 
substitutions in the HA among the Middle East 2009 H1N1 
pdm isolates analyzed. Location of these mutations are in Ca 
antigenic site D-225G, D-225E and R-209-K. Two of these 
D-225E and R-209-K may have little effect on antigenicity, 
due to D and E are hydrophilic negatively charged amino 
acids, while both R and K are hydrophilic positively charged 
amino acids. A unique mutation in 32/39 HA S206T of the ME 
2009 H1N1 pdm isolates was neither found in 1918 and 1977 
H1N1 pdm viruses, nor was it found in the human, swine and 
avian Influenza A viruses[33]. However, It was found that the 
S206T mutation transiently appeared in the HA sequences 
of human H1N1 viruses collected in 1934 and in swine 
H1N1 viruses collected in 1976 and 1977. S206T is located 
in the receptor-binding domain of HA which is a major 
determinant of Influenza A virus host specificity; therefore, 
HA-206 S→T mutation may directly affect the infectivity 
and transmissibility of 2009 H1N1 pdm in humans[33]. The 
N-linked glycosylation is conserved among various HA 
subtypes of influenza A viruses[20]. The ME 2009 H1N1 
pdm isolates have five N-linked glycosylation sequences 
while H1N1 isolates 2007 have seven. It was suggested 
that the presence or absence of N-linked glycosylation 
may cause increase or loss of function of the glycoprotein 
because N-linked glycosylation can initiate and maintain 
folding, stability, solubility, transportation, antigenicity, 
and immunogenicity of the protein[34]. The apparent lack of 
glycosylation at some positions between the ME 2009 H1N1 
pdm isolates and seasonal H1N1 2007 may lead to differences 
in three dimensional structure of these viruses[35], taken 
into consideration that the oligosaccharides are capable of 
masking some antigenic determinants on HA surface and 
therefore modifying the HA reactivity[22,36].  
  In conclusion, the phylogenetic analysis showed ME 
2009 H1N1 pdm isolates are closely related to the recent 
prototype vaccine strain 2010/2011 A/California/07/2009 
(H1N1)-like strain. Taken together, the current influenza 
vaccine is expected to provide a good protection against ME 
2009 H1N1 pdm because it contains strains with H1 HA (A/
California/07/2009 (H1N1)-like strain.
Conflict of interest statement
  The authors declare no competing interest with the present 
work.
References
  [1]   Osterhaus AD, Rimelzwaan GF, Martina BE, Bestebroer TM, 
Fouchier RA. Influenza B in seals. Science 2000; 288: 1051-3.
  [2]   Wright PF, Webster RG. Orthomyxoviruses. In: Fields KDM, 
Hawley BN. (eds.). Virology. Philadelphia: Lippencott-Raven; 
2001, p. 1533-79.
  [3]   Choi C, Ha SK, Chae C. Detection and isolation of H1N1 
influenza virus from pigs in Korea. Vet Rec 2004; 154: 274-5.
  [4]   Fouchier RAV, Munster A, Wallensten TM, Bestebroer S, Herfst 
D, Smith GF, et al. Characterization of a novel influenza virus 
hemagglutinin subtype (H16) obtained from black-headed gulls. 
J Virol 2005; 79: 2814-22.
  [5]   Ma W, Gramer M, Rossow K, Yoon KJ. Isolation and genetic 
characterization of new reassortant H3N1 swine influenza virus 
from pigs in the Midwestern United States. J Virol 2006; 80: 
5092-6.
  [6]   Widjaja L, Krauss SL, Webby RJ, Xie T, Webster RG. Matrix 
gene of influenza A viruses isolated from wild aquatic birds: 
Ecology and emergence of influenza A viruses. J Virol 2004; 78: 
8771-9.
  [7]   Peiris JSM, Guan Y, Markwell D, Ghose P, Webster RG, 
Shortridge KF. Cocirculation of avian H9N2 and contemporary 
“human” H3N2 influenza A viruses in pigs in southeastern 
Ghaleb Adwan./Asian Pacific Journal of Tropical Medicine (2010)624-628628
China: potential for genetic reassortment? J Virol 2001; 75: 
9679-86.
  [8]   Brown IH. The epidemiology and evolution of influenza viruses 
in pigs. Vet Microbiol 2000; 74: 29-46.
  [9]   Stephenson I, Zambon M. The epidemiology of influenza. Occup 
Med (Lond) 2002; 52: 241-7.
[10]   Taubenberger JK, Hultin JV, Morens DM. Discovery and 
characterization of the 1918 pandemic influenza virus in 
historical context. Antivir Ther 2007; 12 (4 Pt B): 581-91.
[11]   Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, 
et al. Antigenic and genetic characteristics of swine-origin 2009 
A(H1N1) influenza viruses circulating in humans. Science 2009; 
325: 197-201.
[12]   Smith GJD, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, 
Pybus OG, et al. Origins and evolutionary genomics of the 2009 
swine-origin H1N1 influenza A epidemic. Nature 2009; 459: 
1122-5.
[13]   Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, et al. 
In vitro and in vivo characterization of new swine-origin H1N1 
influenza viruses. Nature 2009; 460: 1021-5.
[14]   Centers for Disease Control and Prevention. Swine influenza A 
(H1N1) infection in two children-Southern California, March-
April 2009. MMWR 2009a; 58: 400-2.
[15]   Centers for Disease Control and Prevention. Novel H1N1 flu 
situation update July 10, 2009. 2009b.[Online]. Available from: 
http://www.cdc.gov/h1n1flu/updates/071009.htm [Accessed on 
May 15, 2010]. 
[16]   Lalle E, Bordi L, Castilletti C, Meschi S, Selleri M, Carletti F, 
et al. Design and clinical application of a molecular method for 
detection and typing of the influenza A/H1N1pdm virus. J Virol 
Methods 2010; 163: 486-8.
[17]   World Health Organization (WHO). Recommended viruses for 
influenza vaccines for use in the 2010-2011 northern hemisphere 
influenza season, 2010.[Online]. Available from:http://www.who.
int/csr/disease/influenza/recommendations2010_11north/en/
index.html [Accessed on May 15, 2010].
[18]   Chi XS, Bolar TV, Zhao P, Tam JS, Rappaport R, Cheng SM. 
Molecular evolution of human influenza A/H3N2 virus in Asia 
and Europe from 2001 to 2003. J Clin Microbiol 2005; 43: 
6130-2.
[19]   Subbaral K, Joseph T. Scientific barriers to developing vaccines 
against avian influenza viruses. Nature 2007; 7: 267-8.
[20]   Chu t in imi tku l  S ,  Ch ieochans in  T ,  Payungpo rn  S , 
Samransamruajkit R, Hiranras T, Theamboonlers A, et al. 
Molecular characterization and phylogenetic analysis of H1N1 
and H3N2 human influenza A viruses among infants and 
children in Thailand. Virus Res 2008; 132: 122-31.
[21]   Potdar VA, Chadha MS, Jadhav SM, Mullick J, Cherian SS, 
Mishra AC. Genetic characterization of the influenza A pandemic 
(H1N1) 2009 virus isolates from India. PLoS One 2010; 5(3): 
e9693.
[22]   Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson 
JC, Wilson IA. Structure and receptor specificity of the 
hemagglutinin from an H5N1 influenza virus. Science 2006; 312: 
404-10.
[23]   Stevens J, Corper AL, Basler CF, Taubenberger JK, Palese P, 
Wilson IA. Structure  of the uncleaved human H1 hemagglutinin 
from the extinct 1918 influenza virus.  Science 2004; 303: 1866-
70.
[24]   Matrosovich M, Tuzikov A, Bovin N, Gambaryan A, Klimov 
A, Castrucci MR, et al. Early alterations of the receptor-
binding properties of H1, H2, and H3 avian influenza virus 
hemagglutinins after their introduction into mammals. J Virol 
2000; 74: 8502-12.
[25]   Mochalova L, Gambaryan A, Romanova J, Tuzikov A, Chinarev 
A, Katinger D, et al. Receptor binding properties of modern 
human influenza viruses primarily isolated in Vero and MDCK 
cells and chicken embryonated eggs. Virology 2003; 313: 473-
80.
[26]   Gamblin SJ, Haire LF, Russell RJ, Stevens DJ, Xiao B, Ha Y, 
et al. The structure and receptor-binding properties of the 1918 
influenza hemagglutinin. Science 2004; 303: 1838-42.
[27]   Gambaryan AS, Karasin AI, Tuzikov AB, Chinarev AA, Pazynina 
GV, Bovin NV. Receptor-binding properties of swine influenza 
viruses isolated and propagated in MDCK cells. Virus Res 2005; 
114: 1-2.
[28]   Neumann G, Noda T, Kawaoka Y. Emergence and pandemic 
potential of Swine-Origin H1N1 Influenza viruses. Nature 2009; 
459: 931-9.
[29]   Chen GW, Shih SR. Genomic signatures of influenza A pandemic 
(H1N1) 2009 virus. Emerg Infect Dis 2009; 15: 1897-903.
[30]   Skehel JJ, Wiley DC. Receptor binding and membrane fusion 
in virus entry: the influenza hemagglutinin. Annu Rev Biochem 
2000; 69: 531-69.
[31]   Parrish CR, Kawaoka Y. The origins of new pandemic viruses: 
the acquisition of new host ranges by canine parvovirus and 
influenza Aviruses. Annu Rev Microbiol 2005; 59: 553-86.
[32]   Yu H, Zhou YJ, Li GX, Zhang GH, Liu HL, Yan LP, et al. 
Further evidence for infection of pigs with human-like H1N1 
influenza viruses in China. Virus Res 2009; 140: 85-90.
[33]   Pan C, Cheung B, Tan S, Li C, Li L, Liu S, et al. Genomic 
signature and mutation trend analysis of pandemic (H1N1) 2009 
influenza A virus. PLoS One 2010; 5(3): e9549.
[34]   Panda A, Elankumaran S, Krishnamurthy S, Huang Z, Samal 
S. Loss of N-linked glycosylation from the hemagglutinin-
neuraminidase protein alters virulence of Newcastle disease 
virus. J Virol 2004; 78: 4965-75.
[35]   Lin T, Wang G, Li A, Zhang Q, Wu C, Zhang R, et al. The 
hemagglutinin structure of an avian H1N1 influenza A virus. 
Virology 2009; 392: 73-81.
[36]   Al Faress S, Cartet G, Ferraris O, Norder H, Valette M, Lina 
B. Divergent genetic evolution of hemagglutinin in influenza A 
H1N1 and A H1N2 subtypes isolated in the south-France since 
the winter of 2001-2002. J Clin Virol. 2005; 33(3): 230-6.
